ClinicalTrials.gg
CompletedNCT03503773Updated May 14, 2025Results posted

The TARGET BP OFF-MED Trial

A Phase 2 interventional study of Alcohol and Sham control in Hypertension and Hypertension,Essential, sponsored by Ablative Solutions, Inc.. Completed at 4 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Primary conditionEssential HypertensionRegistry: HypertensionReclassifiedWhy we changed it
Registry
Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Essential Hypertension
Why
  1. The study's listed conditions name Essential Hypertension, a narrower term within Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Ablative Solutions, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Essential Hypertension with a site in Belgium — 1 open to participants now, 3 under way, none of them phase 3. Essential Hypertension · Belgium.

Enrollment
8th of 14
350 · median 394
Started
2018
with 2 others
Phase 2
3 of 14
none open now
Registered
11th of 14
by date
Lead sponsor
1 of 14
Ablative Solutions, Inc.

Among the 14 studies in Essential Hypertension with a site in Belgium, this one is the 8th largest by enrollment, is one of 3 that started in 2018, is one of 3 in phase 2, and was the 11th registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

1 of the 14 studies in Essential Hypertension with a site in Belgium is open now. Recruiting first, the newest first:

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 44 Essential Hypertension studies recruiting now, 16 (36%) set no upper age limit and 20 (45%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Essential Hypertension with a site in Belgium, or all of them as a file.
02

Study summary

To obtain an assessment of the efficacy and safety of renal denervation by alcohol-mediated neurolysis using the Peregrine Kit in hypertensive subjects in the absence of antihypertensive medications.

03

Conditions studied

  • Hypertension
  • Hypertension,Essential

Browse trials for

Keywords

  • Renal Denervation
  • Neurolysis
04

In context

Essential Hypertension Reclassified

480 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

This study's enrollment of 350 is above the median of 144 across 406 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

Ablative Solutions, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Essential Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has 3 office blood pressure measurements with a mean office systolic blood pressure (SBP) of ≥140 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of ≥90 mmHg.
  2. Subject is willing to discontinue any current antihypertensive medications during the run-in period and the post-treatment period.
  3. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings

Exclusion criteria

Exclusion Criteria:

  1. Subject has renal artery anatomy abnormalities.
  2. Subject has an estimated (eGFR) of ≤45 mL/min/1.73 m2, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or is on chronic renal replacement therapy.
  3. Subject has documented sleep apnea.
  4. Subject has any of the following conditions: severe cardiac valve stenosis, heart failure ( [NYHA] Class III or IV), chronic atrial fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or right ventricular systolic pressure).
  5. Subject is pregnant or lactating at the time of enrollment or planning to become pregnant during the trial time period (female subjects only).
  6. Subject is being treated chronically (e.g. daily use) with NSAIDs, medications, or immunosuppressive doses of . Aspirin therapy and nasal pulmonary inhalants are allowed.
  7. Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/ within 6 months prior to the planned procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
350 participants (actual)

Study arms

  • Experimental
    Treatment Arm:

    Renal denervation (using the Peregrine Kit) performed with alcohol infused through the Peregrine Catheter

    Drug: Alcohol

  • Sham comparator
    Sham Control Arm

    Only renal angiography performed

    Other: Sham control

Interventions

  • Alcohol is directly infused/delivered to the adventitial and periadventitial space of the renal arteries

  • OtherSham control

    endovascular, renal angiography

07

What researchers measure

Primary outcomes

  1. Changes in Systolic Ambulatory Blood Pressure

    Change from baseline in mean 24-hour ambulatory systolic blood pressure

    Time frame: Baseline to 8 weeks post-treatment

Secondary outcomes

  1. Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months

    Change from baseline in mean 24-hour ambulatory systolic blood pressure from baseline to 6 months

    Time frame: 6 months

  2. Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months

    Change from baseline in mean 24-hour systolic blood pressure at 12 months post-procedure

    Time frame: 12 months

  3. Change in Office SBP at 8 Weeks

    Change from Baseline in mean office SBP to Week 8

    Time frame: 8 weeks

  4. Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks

    Change from baseline in mean 24-hour ambulatory diastolic blood pressure and 8 weeks post-procedure

    Time frame: 8 weeks

  5. Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months

    Change from baseline in mean 24-hour ambulatory diastolic blood pressure at 6 months post-procedure

    Time frame: 6 months

  6. Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months

    Change from baseline in mean 24-hour diastolic blood pressure 12 months post-procedure

    Time frame: 12 months

  7. Number of Participants With Major Adverse Events (MAEs)

    Number of participants with major adverse events (MAEs) 30 days post-procedure

    Time frame: 30 days post procedure

  8. Use of Antihypertensive Medication(s)

    Use of antihypertensive medication at 8 weeks

    Time frame: 8 weeks

  9. Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks

    Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 8 Weeks

    Time frame: 8 weeks

  10. Change in Mean Daytime Ambulatory Systolic Blood Pressure at 6 Months

    Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months

    Time frame: 6 months

  11. Change in Mean Daytime Ambulatory Systolic Blood Pressure at 12 Months

    Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 12 Months

    Time frame: 12 months

  12. Mean Daytime Ambulatory Diastolic Blood Pressure

    Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 8 Weeks

    Time frame: 8 weeks

  13. Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 6 Months

    Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 6 months

    Time frame: 6 months

  14. Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 12 Months

    Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 12 Months

    Time frame: 12 months

  15. Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 8 Weeks

    Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 8 Weeks

    Time frame: 8 weeks

  16. Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 6 Months

    Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 6 Months

    Time frame: 6 months

  17. Change in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months

    Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months

    Time frame: 12 months

  18. Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 8 Weeks

    Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 8 weeks

    Time frame: 8 weeks

  19. Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 6 Months

    Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 6 Months

    Time frame: 6 months

  20. Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 12 Months

    Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 12 Months

    Time frame: 12 months

  21. Change in Mean Office SBP at 6 Months

    Change from Baseline in mean office SBP to 6 Months

    Time frame: 6 months

  22. Change in Mean Office SBP to 12 Months

    Change from Baseline in mean office SBP to 12 Months

    Time frame: 12 months

  23. Change in Mean Office DBP to 8 Weeks

    Change from Baseline in mean office DBP to 8 Weeks

    Time frame: 8 weeks

  24. Change in Mean Office DBP to 6 Months

    Change from Baseline in mean office DBP to 6 Months

    Time frame: 6 months

  25. Change in Mean Office DBP at 12 Months

    Change from Baseline in mean office DBP to 12 Months

    Time frame: 12 months

08

Results

Posted Oct 4, 2024

Participant flow

Participant flow — Overall Study
MilestoneSham Control ArmTreatment Arm:
Started5650
Completed4443
Not completed127
Withdrew: Not receiving bilateral treatment or an unsuccessful procedure02
Withdrew: Receiving antihypertensive medications prior to evaluation of the primary abpm84
Withdrew: Not completing the primary abpm31
Withdrew: Not meeting inclusion/exclusion criteria10

Outcome measures

PrimaryChanges in Systolic Ambulatory Blood Pressure

Change from baseline in mean 24-hour ambulatory systolic blood pressure

Time frame:
Baseline to 8 weeks post-treatment
Reported as:
Mean · mmHg
Changes in Systolic Ambulatory Blood Pressure
mmHgSham Control ArmTreatment Arm:
Changes in Systolic Ambulatory Blood Pressure-1.4 ± 8.6-2.9 ± 7.4
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · ANCOVA · p = 0.2682 · Mean difference (final values): -1.5 · 95% CI -4.8 to 1.7There was no formal hypothesis testing conducted in the study. 95% CIs are intended to be descriptive in nature only
SecondaryChange in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months

Change from baseline in mean 24-hour ambulatory systolic blood pressure from baseline to 6 months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean 24-Hour Ambulatory Systolic Blood Pressure135.1 ± 11.7134.1 ± 11.6
Change from baseline in Mean 24-Hour Ambulatory Systolic Blood Pressure-13.4 ± 12.9-13.9 ± 11.6
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · ANCOVA · p = 0.6964
SecondaryChange in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months

Change from baseline in mean 24-hour systolic blood pressure at 12 months post-procedure

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean 24-Hour Ambulatory Systolic Blood Pressure at 12 Months
mmHgSham Control ArmTreatment Arm:
Mean 24-hour SBP133.7 ± 11.3137.6 ± 11.4
Change from baseline in mean 24-hour SBP-15.9 ± 13.1-10.6 ± 11.5
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · ANCOVA · p = 0.0775
SecondaryChange in Office SBP at 8 Weeks

Change from Baseline in mean office SBP to Week 8

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Office SBP at 8 Weeks
mmHgSham Control ArmTreatment Arm:
Office SBP160.6 ± 16.3155.4 ± 14.3
Change from Baseline in mean office SBP0.63 ± 13.24-4.0 ± 12.6
SecondaryChange in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks

Change from baseline in mean 24-hour ambulatory diastolic blood pressure and 8 weeks post-procedure

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 8 Weeks
mmHgSham Control ArmTreatment Arm:
Mean 24-hour ambulatory diastolic blood pressure91.0 ± 6.892.2 ± 7.6
Change from baseline in Mean 24-hour ambulatory diastolic blood pressure-1.1 ± 6.6-2.0 ± 5.1
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · ANCOVA · p = 0.4734
SecondaryChange in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months

Change from baseline in mean 24-hour ambulatory diastolic blood pressure at 6 months post-procedure

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean 24-hour ambulatory diastolic blood pressure83.4 ± 9.083.0 ± 8.4
Change from baseline in Mean 24-hour ambulatory diastolic blood pressure-8.0 ± 8.5-9.3 ± 6.9
SecondaryChange in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months

Change from baseline in mean 24-hour diastolic blood pressure 12 months post-procedure

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean 24-Hour Ambulatory Diastolic Blood Pressure at 12 Months
mmHgSham Control ArmTreatment Arm:
Mean 24-hour ambulatory diastolic blood pressure81.0 ± 7.985.6 ± 8.7
Change from baseline in Mean 24-hour ambulatory diastolic blood pressure-9.8 ± 8.3-7.3 ± 7.5
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · ANCOVA · p = 0.0341
SecondaryNumber of Participants With Major Adverse Events (MAEs)

Number of participants with major adverse events (MAEs) 30 days post-procedure

Time frame:
30 days post procedure
Reported as:
Count of participants · Participants
Number of Participants With Major Adverse Events (MAEs)
ParticipantsSham Control ArmTreatment Arm:
Number of Participants With Major Adverse Events (MAEs)11
SecondaryUse of Antihypertensive Medication(s)

Use of antihypertensive medication at 8 weeks

Time frame:
8 weeks
Reported as:
Mean · medications
Use of Antihypertensive Medication(s)
medicationsSham Control ArmTreatment Arm:
Use of Antihypertensive Medication(s)0.089 ± 0.2880.060 ± 0.240
Statistical analysis
  • Sham Control Arm vs Treatment Arm: · Fisher Exact · p = 0.573 · Mean difference (final values): -0.029 · 95% CI -0.132 to 0.073
SecondaryChange in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks

Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 8 Weeks

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 8 Weeks
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Systolic Blood Pressure153.2 ± 12.0150.6 ± 10.5
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure-1.7 ± 9.9-3.2 ± 9.5
SecondaryChange in Mean Daytime Ambulatory Systolic Blood Pressure at 6 Months

Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Systolic Blood Pressur140.6 ± 12.3139.7 ± 12.8
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 6 Months-14.5 ± 13.7-14.0 ± 13.3
SecondaryChange in Mean Daytime Ambulatory Systolic Blood Pressure at 12 Months

Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Daytime Ambulatory Systolic Blood Pressure at 12 Months
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Systolic Blood Pressure140.1 ± 12.1143.5 ± 12.6
Change from Baseline in Mean Daytime Ambulatory Systolic Blood Pressure-15.5 ± 13.6-10.5 ± 12.8
SecondaryMean Daytime Ambulatory Diastolic Blood Pressure

Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 8 Weeks

Time frame:
8 weeks
Reported as:
Mean · mmHg
Mean Daytime Ambulatory Diastolic Blood Pressure
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Diastolic Blood Pressure94.7 ± 9.795.2 ± 7.5
hange from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure-1.4 ± 6.8-2.3 ± 6.8
SecondaryChange in Mean Daytime Ambulatory Diastolic Blood Pressure at 6 Months

Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 6 months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Diastolic Blood Pressure87.6 ± 9.087.8 ± 9.2
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure-8.9 ± 8.6-9.3 ± 8.9
SecondaryChange in Mean Daytime Ambulatory Diastolic Blood Pressure at 12 Months

Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Daytime Ambulatory Diastolic Blood Pressure at 12 Months
mmHgSham Control ArmTreatment Arm:
Mean Daytime Ambulatory Diastolic Blood Pressure86.0 ± 8.790.4 ± 9.6
Change from Baseline in Mean Daytime Ambulatory Diastolic Blood Pressure-9.5 ± 8.7-7.6 ± 8.9
SecondaryChange in Mean Nighttime Ambulatory Systolic Blood Pressure at 8 Weeks

Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 8 Weeks

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 8 Weeks
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Systolic Blood Pressure136.9 ± 14.6134.4 ± 11.6
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure-0.58 ± 12.17-3.3 ± 9.4
SecondaryChange in Mean Nighttime Ambulatory Systolic Blood Pressure at 6 Months

Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 6 Months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Systolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Systolic Blood Pressure125.6 ± 13.9125.4 ± 12.1
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure-12.8 ± 14.1-13.4 ± 12.7
SecondaryChange in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months

Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Systolic Blood Pressure to 12 Months
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Systolic Blood Pressure123.1 ± 12.3127.8 ± 10.7
Change from Baseline in Mean Nighttime Ambulatory Systolic Blood Pressure-17.1 ± 14.4-11.8 ± 12.2
SecondaryChange in Mean Nighttime Ambulatory Diastolic Blood Pressure at 8 Weeks

Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 8 weeks

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 8 Weeks
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Diastolic Blood Pressure82.5 ± 12.481.5 ± 8.4
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure-0.44 ± 10.17-2.5 ± 7.3
SecondaryChange in Mean Nighttime Ambulatory Diastolic Blood Pressure at 6 Months

Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 6 Months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 6 Months
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Diastolic Blood Pressure75.8 ± 10.875.5 ± 9.2
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure-7.4 ± 10.4-9.0 ± 8.0
SecondaryChange in Mean Nighttime Ambulatory Diastolic Blood Pressure at 12 Months

Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Nighttime Ambulatory Diastolic Blood Pressure at 12 Months
mmHgSham Control ArmTreatment Arm:
Mean Nighttime Ambulatory Diastolic Blood Pressure72.8 ± 8.277.4 ± 7.8
Change from Baseline in Mean Nighttime Ambulatory Diastolic Blood Pressure-10.8 ± 9.7-7.6 ± 8.1
SecondaryChange in Mean Office SBP at 6 Months

Change from Baseline in mean office SBP to 6 Months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Office SBP at 6 Months
mmHgSham Control ArmTreatment Arm:
mean office SBP145.7 ± 14.3146.1 ± 16.4
Change from Baseline in mean office SBP to 6 Months-14.7 ± 15.7-12.9 ± 15.6
SecondaryChange in Mean Office SBP to 12 Months

Change from Baseline in mean office SBP to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Office SBP to 12 Months
mmHgSham Control ArmTreatment Arm:
mean office SBP147.8 ± 15.1147.9 ± 18.5
Change from Baseline in mean office SBP to 12 Months-13.2 ± 16.6-11.0 ± 15.3
SecondaryChange in Mean Office DBP to 8 Weeks

Change from Baseline in mean office DBP to 8 Weeks

Time frame:
8 weeks
Reported as:
Mean · mmHg
Change in Mean Office DBP to 8 Weeks
mmHgSham Control ArmTreatment Arm:
mean office DBP97.3 ± 10.997.0 ± 9.4
Change from Baseline in mean office DBP to 8 Weeks-1.1 ± 8.8-3.5 ± 7.6
SecondaryChange in Mean Office DBP to 6 Months

Change from Baseline in mean office DBP to 6 Months

Time frame:
6 months
Reported as:
Mean · mmHg
Change in Mean Office DBP to 6 Months
mmHgSham Control ArmTreatment Arm:
mean office DBP89.7 ± 10.590.4 ± 9.4
Change from Baseline in mean office DBP to 6 Months-8.4 ± 9.5-10.0 ± 9.0
SecondaryChange in Mean Office DBP at 12 Months

Change from Baseline in mean office DBP to 12 Months

Time frame:
12 months
Reported as:
Mean · mmHg
Change in Mean Office DBP at 12 Months
mmHgSham Control ArmTreatment Arm:
mean office DBP88.5 ± 11.591.0 ± 11.0
Change from Baseline in mean office DBP to 12 Months-9.6 ± 11.0-9.4 ± 9.4

Adverse events

Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sham Control Arm0/56 (0%)9/56 (16.1%)42/56 (75%)
Treatment Arm:0/50 (0%)7/50 (14%)41/50 (82%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventSham Control ArmTreatment Arm:
Atrial fibrillationCardiac disorders0/562/50
Abdominal abscessInfections and infestations0/561/50
Appendicitis perforatedInfections and infestations0/561/50
Post procedural haematomaInjury, poisoning and procedural complications0/561/50
Urethral stenosisRenal and urinary disorders0/561/50
AneurysmVascular disorders0/561/50
HaematomaVascular disorders0/561/50
Hypertensive crisisVascular disorders0/561/50
Vascular pseudoaneurysmInjury, poisoning and procedural complications1/560/50
Haemoglobin decreasedInvestigations1/560/50
Most frequent other events
Showing 10 of 119
Most frequent other events
EventSham Control ArmTreatment Arm:
HeadacheNervous system disorders7/5611/50
Post procedural haematomaInjury, poisoning and procedural complications4/566/50
HaematomaVascular disorders2/565/50
Glomerular filtration rate decreasedInvestigations5/562/50
Back painMusculoskeletal and connective tissue disorders5/562/50
HypertensionVascular disorders5/563/50
NasopharyngitisInfections and infestations4/562/50
Oedema peripheralGeneral disorders1/563/50
Oedema peripheralGeneral disorders3/561/50
Blood pressure increasedInvestigations3/562/50

Baseline characteristics

Age, Continuous
Age, Continuous(years)Treatment Arm:Sham Control ArmTotal
Mean53.8 ± 11.054.4 ± 11.554.1 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm:Sham Control ArmTotal
Female101828
Male403878
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Treatment Arm:Sham Control ArmTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)Treatment Arm:Sham Control ArmTotal
Belgium112
United Kingdom7916
France7613
Germany283058
Netherlands448
Ireland224
United States145
eGFR
eGFR(mL/min per 1.73 m^2)Treatment Arm:Sham Control ArmTotal
Mean85.8 ± 14.085.9 ± 13.085.8 ± 13.4
Diabetes (type 2)
Diabetes (type 2)(Participants)Treatment Arm:Sham Control ArmTotal
Count of participants257
Smoking (current)
Smoking (current)(Participants)Treatment Arm:Sham Control ArmTotal
Count of participants8311
Peripheral vascular occlusive disease
Peripheral vascular occlusive disease(Participants)Treatment Arm:Sham Control ArmTotal
Count of participants112

1 further baseline measures are reported on the registry.

09

Study locations

4 sites
  • Cliniques Universitaires Saint-Luc
    Brussels, 1200, Belgium
  • Clinique Pasteur Toulouse
    Toulouse, France
  • Universitätsklinikum des Saarlandes
    Homburg/Saar, 66421, Germany
  • NIHR Barts Cardiovascular Biomedical Research Unit
    London, EC1M 6BQ, United Kingdom
10

References and documents

Publications

  • Pathak A, Rudolph UM, Saxena M, Zeller T, Muller-Ehmsen J, Lipsic E, Schmieder RE, Sievert H, Halbach M, Sharif F, Parise H, Fischell TA, Weber MA, Kandzari DE, Mahfoud F. Alcohol-mediated renal denervation in patients with hypertension in the absence of antihypertensive medications. EuroIntervention. 2023 Sep 18;19(7):602-611. doi: 10.4244/EIJ-D-23-00088. PubMed 37427416 ↗
  • Bertog S, Sharma A, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V, Weber MA, Haratani N, Lobo MD, Saxena M, Kandzari DE, Fischell TA, Sievert H. Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Infusion Catheter. Cardiovasc Revasc Med. 2021 Mar;24:77-86. doi: 10.1016/j.carrev.2020.09.003. Epub 2020 Sep 7. PubMed 32958438 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Jan 2022, 40 months.

Results were first posted in Oct 2024, 2 years 8 months after primary completion.

Of 15 phase 2 interventional studies under Essential Hypertension, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 40. This study's 40 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Apr 20, 2018
StartActual
Sep 24, 2018
Primary completionActual
Jan 31, 2022
CompletionActual
Jan 10, 2024
Results first posted
Oct 4, 2024
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT03503773
Lead sponsor
Ablative Solutions, Inc.
Responsible party
Sponsor
First posted
Apr 20, 2018
Start date
Sep 24, 2018
Primary completion
Jan 31, 2022
Completion
Jan 10, 2024
Results posted
Oct 4, 2024
Last update
May 14, 2025

Study contacts

Felix Mahfoud, Prof.Dr.med.
principal investigator · Universitätsklinikum des Saarlandes Klinik für Innere Medizin III Kardiologie, Angiologie und Internistische Intensivmedizin, Germany
Atul Pathak, Prof.
principal investigator · Clinique Pasteur Hi-LAB, Toulouse, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethanol

Start the discussion